Latest:
Contributor: The Enemy of Your Enemy Should Be Your Friend – Why Biosimilars Companies Should Collaborate
© 2022 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest:
Contributor: The Enemy of Your Enemy Should Be Your Friend – Why Biosimilars Companies Should Collaborate
Latest:
Opinion: Efforts to Improve Biosimilars Education Are a Start, but Payer Policies Must Catch Up
Latest:
Contributor: No Good Deed Goes Unpunished—How PBM Mandates Increase Practice Variability
Latest:
Opinion: Biosimilar Adoption Will Help Achieve a Bipartisan Goal
Latest:
The US Is Entering Round 2 of Biosimilar Activity, Says Cardinal Health’s Oskouei
Latest:
Opinion: The Legal and Regulatory Year in Review
Latest:
Legal Opinion: BPCIA Is Likely to Survive Latest ACA Challenge
Latest:
Opinion: Purple Book Patent Listings Are Only a First Step